<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371355</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 703802-CS2</org_study_id>
    <nct_id>NCT03371355</nct_id>
  </id_info>
  <brief_title>Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to
      evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of
      different doses and dosing regimens of ISIS 703802 on glucose and lipid metabolism, and liver
      fat in subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic
      Fatty Liver Disease (NAFLD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in fasting TG level from Baseline at the primary analysis time point.</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis will be the pairwise comparison of percent change from Baseline to primary analysis time point in TG between ISIS 703802 treatment groups and pooled placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of ISIS 703802 by the incidence of treatment-emergent adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>The safety of ISIS 703802 will be assessed by determining adverse effects by dose. Safety results in subjects dosed with ISIS 703802 will be compared with those from subjects dosed with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on glucose metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis will be the change at the primary analysis time point in blood glucose metabolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ISIS 703802 on changes from Baseline at End-of-Treatment lipid metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis will be the change at the primary analysis time point in markers of lipid metabolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on liver fat</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis will be the change of hepatic fat fraction (HFF) by MRI-PDFF compared between each ISIS 703802 treatment groups and pooled. placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cmax of ISIS 703802 across different doses and dose regimens</measure>
    <time_frame>6 months</time_frame>
    <description>Cmax of ISIS 703802 in plasma will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Tmax of ISIS 703802 across different doses and dose regimens</measure>
    <time_frame>6 months</time_frame>
    <description>Tmax of ISIS 703802 in plasma will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AUC values of ISIS 703802 across different doses and dose regimens</measure>
    <time_frame>6 months</time_frame>
    <description>Plasma AUC values of ISIS 703802 will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ISIS 703802 on changes from Baseline on biomarkers related to liver inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute change in ALT and AST and various markers of liver inflammation and fibrosis will be compared between each ISIS 703802 treatment group and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ISIS 703802 on changes from Baseline on adipose tissue as related to body composition</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute change in body composition as measured by single slice MRI of adipose tissue will be compared between each ISIS 703802 treatment group and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ISIS 703802 on changes from Baseline on WHR (waist-to-hip ratio) as related to body composition.</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute change in Body composition as measured WHR (waist-to-hip ratio) will be compared between each ISIS 703802 treatment group and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ISIS 703802 on changes from Baseline on BMI (Body Mass Index) as related to body composition</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute change in Body composition as measured by BMI will be compared between each ISIS 703802 treatment group and pooled placebo group.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>NAFLD</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Fatty Liver, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>ISIS 703802 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 703802 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 703802 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Sterile Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Normal Saline (0.9% NaCl) by volume to match dose and regimen of active comparator depending on Cohort assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 703802</intervention_name>
    <description>Randomly assigned to one of the dosing cohorts.</description>
    <arm_group_label>ISIS 703802 Dose 1</arm_group_label>
    <arm_group_label>ISIS 703802 Dose 2</arm_group_label>
    <arm_group_label>ISIS 703802 Dose 3</arm_group_label>
    <other_name>AKCEA-ANGPTL3-LRx, IONIS-ANGPTL3-LRx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomly assigned to one of the dosing cohorts. Dose of placebo in each cohort will match volume of active in that cohort.</description>
    <arm_group_label>Placebo: Sterile Normal Saline</arm_group_label>
    <other_name>Sterile Normal Saline (0.9% NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plasma TG at Screening &gt; 200 mg/dL and at qualification of ≥ 150 mg/dL

          -  Documented history of hepatic steatosis with baseline MRI indicating hepatic fat
             fraction (HFF) ≥ 10%

          -  Diagnosis of Type 2 Diabetes Mellitus with Hemoglobin A1c ≥ 7 and ≤ 10% at Screening

          -  Must have been on a stable dose of Oral Antidiabetic Therapy for a minimum of 3 months
             prior to Screening

          -  Body mass index between 27- 40 kg/m2, inclusive, at Screening

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Active chronic liver disease, alcoholic liver disease, Wilson's disease
             hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, genetic
             hemochromatosis, known or suspected hepatocellular carcinoma, history of or planned
             liver transplant for end-stage liver disease of any etiology

          -  Documented history of advanced liver fibrosis

          -  History of cirrhosis and/or hepatic decompensation including ascites, hepatic
             encephalopathy, or variceal bleeding

          -  History of clinically significant acute cardiac event within 6 months before Screening

          -  History of heart failure with NYHA greater than Class II

          -  Use of Insulin or insulin analogs, GLP-1 agonists, and PPARᵞ agonists (pioglitazone or
             rosiglitazone)

          -  Weight change &gt; 5% within 3 months before Screening

          -  Conditions contraindicated for MRI procedures including any metal implant (e.g., heart
             pacemaker, rods, screws, aneurysm clips)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akcea Therapeutics</last_name>
    <phone>617-207-0289</phone>
    <email>clinicalstudies@akceatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Hepatic Steatosis</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>AKCEA-ANGPTL3-Lrx</keyword>
  <keyword>IONIS-ANGPTL3-Lrx</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Fatty Liver Without Mention of Alcohol</keyword>
  <keyword>Liver Fat</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Diabetes Mellitus Type 2 in Nonobese</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Triglycerides High</keyword>
  <keyword>High Triglycerides</keyword>
  <keyword>Metabolic Disease</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Digestive System Disease</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

